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Objectives: HLA-A*31:30 and HLA-B*40:55 are two rarely observed alleles in the HLA-A locus and HLA-B
locus, respectively. The objective of this study is to report three deduced probable human leukocyte
antigen (HLA) haplotypes in association with HLA-A*31:30 and HLA-B*40:55 in unrelated bone marrow
hematopoietic stem cell donors.
Materials and methods: A sequence-based typing method was used to conﬁrm the two low-incidence
alleles observed. A polymerase chain reaction was performed to amplify exons 2, 3, and 4 of the HLA-
A, -B, and -C loci and exon 2 of the HLA-DRB1 locus with group-speciﬁc primer sets. Amplicons were
sequenced using the BigDye Terminator Cycle Sequencing Ready Reaction Kit in both directions ac-
cording to the manufacturer’s protocols.
Results: The DNA sequence of A*31:30 is identical to A*31:01:02 in exons 2, 3, and 4, except for a
nucleotide substitution at residue 539 (T/G) resulting in an amino acid replacement at position 156
(Leu/Trp). We deduced the probable HLA haplotype in association with A*31:30 as A*31:30-B*15-
DRB1*14. The DNA sequence of B*40:55 is identical to B*40:01:01 in exons 2, 3, and 4 except for a
nucleotide exchange at residue 814 (G/A) resulting in an amino acid substitution at position 248
(Val/Met). Two probable HLA haplotypes associated with B*40:55 may be deduced as A*02:07-
B*40:55-DRB1*04:05 and A*26:01-B*40:55-DRB1*09:01.
Conclusion: Information about the deduced HLA haplotypes associated with the rare A*31:30 and
B*40:55 alleles that we reported here is valuable for HLA tissue typing laboratories for reference pur-
poses and for stem cell transplantation donor search coordinators to determine the likelihood of ﬁnding
compatible donors in unrelated bone marrow donor registries for patients bearing these two uncommon
HLA alleles. Because A*31:30 and B*40:55 have been found in Taiwanese population so far, we think the
haplotypes that we reported here are most likely conserved in their population.
Copyright  2013, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
The major histocompatibility complex (MHC) in humans con-
sists of several loci of genes located on the short arm of chromo-
some 6 at 6p21.3. These loci are classiﬁed into Class I, II, and III oflls Center, Buddhist Tzu Chi
Hualien, Taiwan. Tel.: þ886
).
ddhist Compassion Relief Tzu Chithe MHC and the genes of human leukocyte antigen (HLA) alleles
are situated in the MHC Class I and II regions. The HLA genes are
characterized by their extreme allelic polymorphism and their
variations and diversity among different ethnic groups and racial
populations. As the HLA molecule similarity between donors and
recipients is being used as a prediction factor for graft survival and
graft-versus-host disease, it is imperative to characterize precisely
any new allele encountered during routine HLA typing procedures.
To facilitate successful and comprehensive unrelated bone marrow
donor searches for patients in need of hematopoietic stem cell
transplantation, we are persistently working on resolvingFoundation. Published by Elsevier Taiwan LLC. All rights reserved.
cDNA 80  90 100 110  120 130 140 150 160 170
A*31:01:02 GCTCCCA CTCCATGAGG TATTTCACCA CATCCGTGTC CCGGCCCGGC CGCGGGGAGC CCCGCTTCAT CGCCGTGGGC TACGTGGACG ACACGCAGTT
A*31:30 ------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
cDNA  180 190 200 210  220 230 240 250 260 270
A*31:01:02 CGTGCGGTTC GACAGCGACG CCGCGAGCCA GAGGATGGAG CCGCGGGCGC CGTGGATAGA GCAGGAGAGG CCTGAGTATT GGGACCAGGA GACACGGAAT
A*31:30 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
cDNA  280 290 300 310  320 330 340 350  360 370
A*31:01:02 GTGAAGGCCC ACTCACAGAT TGACCGAGTG GACCTGGGGA CCCTGCGCGG CTACTACAAC CAGAGCGAGG CCG|GTTCTCA CACCATCCAG ATGATGTATG
A*31:30 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---|------- ---------- ----------
cDNA  380 390 400 410  420 430 440 450 460 470
A*31:01:02 GCTGCGACGT GGGGTCGGAC GGGCGCTTCC TCCGCGGGTA CCAGCAGGAC GCCTACGACG GCAAGGATTA CATCGCCTTG AACGAGGACC TGCGCTCTTG
A*31:30 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
cDNA  480 490 500 510  520 530 540 550 560 570
A*31:01:02 GACCGCGGCG GACATGGCGG CTCAGATCAC CCAGCGCAAG TGGGAGGCGG CCCGTGTGGC GGAGCAGTTG AGAGCCTACC TGGAGGGCAC GTGCGTGGAG
A*31:30 ---------- ---------- ---------- ---------- ---------- ---------- --------G- ---------- ---------- ----------
cDNA  580 590 600 610
A*31:01:02 TGGCTCCGCA GATACCTGGA GAACGGGAAG GAGACGCTGC AGCGCACGG
A*31:30 ---------- ---------- ---------- ---------- ---------
Fig. 1. Comparison of DNA sequences between HLA-A*31:30 and -A*31:01:02 in exons 2 and 3. The DNA sequence of A*31:30 is identical to A*31:01:02 in exons 2 and 3, except at
residue 539 where the T of A*31:01:02 is replaced by G (shaded). cDNA ¼ complementary DNA.
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vices for HLA matching and donor selection.
HLA-A*31:30 and HLA-B*40:55 were ﬁrst reported to the im-
munogenetics (IMGT)/HLA database in 2010 and 2004, respectively
[1], without an indication of probable HLA-associated haplotypes.
Here we report the deduced probable HLA haplotypes in associa-
tion with A*31:30 and B*40:55. We further postulate that the
deduced plausible HLA haplotype in association with A*31:30 is
most likely conserved in the Taiwanese population, based on its low
frequency in the general population and the fact that it has so far
been reported only in a Taiwanese population [1]. Similarly, the
deduced probable B*40:55-associated HLA haplotype A*02:07-
B*40:55-DRB1*04:05 is most likely conserved in the Taiwanese
population, whereas the other deduced probable B*40:55-
associated haplotype, A*26:01-B*40:55-DRB1*09:01, is conserved
in Japanese and Taiwanese populations.2. Materials and methods
Peripheral whole blood samples from three unrelated bone
marrow stem cell donors with Taiwanese ethnicity were collected
in acid citrate dextrose (ACD) anticoagulant. Formal written con-
sents were signed by the donors before blood collection. The ACD
whole blood was stored at e80 C until use. Genomic DNA was
extracted using the QIAamp DNA Blood Mini Kit according to the
manufacturer’s instructions (Qiagen, Hilden, Germany). Genomic
DNA typing of HLA-A, -B, and -DRB1 loci was ﬁrst performed
using Dynal Reli-sequence-speciﬁc oligonucleotide probe (SSO)
HLA-A, -B, and -DRB1 Typing Kits (Dynal Biotech, Bromborough,
Wirral, UK), followed by the sequence-speciﬁc primer (SSP) typing
method (AllSet Gold SSP HLA high-resolution kits; Dynal Biotech,
Invitrogen, Brown Deer, WI, USA) to reach high-resolution allelic
subtypes. The sequence-based typing method [2e6] was used to
conﬁrm the low-incidence alleles observed, and in cases of anom-
alous results and typing ambiguities from the SSO and SSP typingAA Pos. 10 20  30  40
A*31:01:02  GSHSMRYFTT SVSRPGRGEP RFIAVGYVDD TQFVRFDSDA ASQRME
A*31:30  *--------- ---------- ---------- ---------- ------
AA Pos. 110  120 130 140
A*31:01:02  CDVGSDGRFL RGYQQDAYDG KDYIALNEDL RSWTAADMAA QITQRK
A*31:30  ---------- ---------- ---------- ---------- ------
Fig. 2. Comparison of amino acid sequences between HLA-A*31:30 and -A*31:01:02 in exon
3, except at residue 156 where the L of A*31:01:02 is replaced by W (shaded). HLA ¼ humprotocols. Polymerase chain reaction was carried out to amplify
exons 2, 3, and 4 of the HLA-C locus and exon 2 of the DQB1 locus
with group-speciﬁc primer sets as previously described [7].
Amplicons were sequenced by the BigDye Terminator Cycle
Sequencing Ready Reaction Kit (Applied Biosystems, Foster City, CA,
USA) in both directions. In this study, A*31:30 from one blood
donor and B*40:55 from another two blood donors were
sequenced and analyzed.3. Results
We conﬁrmed that the DNA sequence of A*31:30 is identical to
A*31:01:02 in exons 2, 3, and 4, except for a nucleotide substitution
at residue 539 (T/G) [1] (Fig.1). The nucleotide substitution caused
an amino acid replacement at residue 156 (Leu/Trp; Fig. 2). The
extended HLA typing of our donor carrying A*31:30 was A*02:07,
A*31:30, B*15:01, B*46:01, DRB1*09:01, and DRB1*14:05. Together
with the HLA typing of the cell (328573) with A*31:30 reported to
the IMGT/HLA database by Yang et al (A*11:01, A*31:30, B*15,
DRB1*14, and DRB1*16) [1], the probable HLA haplotype in asso-
ciation with A*31:30 may be deduced as A*31:30-B*15-DRB1*14.
Historically, we detected three unrelated bonemarrow stem cell
donors bearing the B*40:55 allele in our bone marrow donor reg-
istry. We conﬁrmed that the DNA sequence of B*40:55 is identical
to B*40:01:01 in exons 2, 3, and 4 except for a nucleotide substi-
tution at position 814 (G/A; Fig. 3). The nucleotide replacement
resulted in an amino acid substitution at position 248 (Val/Met;
Fig. 4). The extended HLA typing of the three bone marrow donors
was as follows: A*02:07, A*33:03, B*40:55, B*46:01, DRB1*04:05,
DRB1*09:01; A*02:07, B*40:55, B*51:01, DRB1*04:05, DRB1*11:01;
and A*24:02, A*26:01, B*40:55, B*46:01, DRB1*04:05, DRB1*09:01.
Together with the extended HLA typing of the Japanese donor (TBC
46239) bearing B*40:55 reported to the IMGT/HLA database
(A*24:02, A*26:01, B*40:01, B*40:55, DRB1*09:01, DRB1*15:01)
[1], the following two plausible HLA haplotypes associated with50 60   70  80  90 100
PRAP WIEQERPEYW DQETRNVKAH SQIDRVDLGT LRGYYNQSEA GSHTIQMMYG
---- ---------- ---------- ---------- ---------- ----------
150   160  170 180
WEAA RVAEQLRAYL EGTCVEWLRR YLENGKETLQ RT
---- -----W---- ---------- ---------- --
s 2 and 3. The amino acid sequence of A*31:30 is identical to A*31:01:02 in exons 2 and
an leukocyte antigen.
cDNA 80 90 100 110 120 130 140 150 160 170
B*40:01:01 GCTCCCA CTCCATGAGG TATTTCCACA CCGCCATGTC CCGGCCCGGC CGCGGGGAGC CCCGCTTCAT CACCGTGGGC TACGTGGACG ACACGCTGTT
B*40:55 ------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
cDNA 180 190 200 210 220 230 240  250 260 270
B*40:01:01 CGTGAGGTTC GACAGCGACG CCACGAGTCC GAGGAAGGAG CCGCGGGCGC CATGGATAGA GCAGGAGGGG CCGGAGTATT GGGACCGGGA GACACAGATC
B*40:55 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
cDNA 280 290 300 310 320 330 340 350 360 370
B*40:01:01 TCCAAGACCA ACACACAGAC TTACCGAGAG AGCCTGCGGA ACCTGCGCGG CTACTACAAC CAGAGCGAGG CCG|GGTCTCA CACCCTCCAG AGGATGTACG
B*40:55 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---|------- ---------- ----------
cDNA 380 390 400 410 420 430 440 450 460 470
B*40:01:01 GCTGCGACGT GGGGCCGGAC GGGCGCCTCC TCCGCGGGCA TAACCAGTAC GCCTACGACG GCAAGGATTA CATCGCCCTG AACGAGGACC TGCGCTCCTG
B*40:55 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
cDNA 480 490 500 510 520 530 540 550 560 570
B*40:01:01 GACCGCCGCG GACACGGCGG CTCAGATCTC CCAGCGCAAG TTGGAGGCGG CCCGTGTGGC GGAGCAGCTG AGAGCCTACC TGGAGGGCGA GTGCGTGGAG
B*40:55 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
cDNA 580 590 600 610 620 630 640 650  660 670
B*40:01:01 TGGCTCCGCA GATACCTGGA GAACGGGAAG GACAAGCTGG AGCGCGCTG|A CCCCCCAAAG ACACACGTGA CCCACCACCC CATCTCTGAC CATGAGGCCA
B*40:55 ---------- ---------- ---------- ---------- ---------|- ---------- ---------- ---------- ---------- ----------
cDNA 680 690 700 710 720 730 740 750 760 770
B*40:01:01 CCCTGAGGTG CTGGGCCCTG GGTTTCTACC CTGCGGAGAT CACACTGACC TGGCAGCGGG ATGGCGAGGA CCAAACTCAG GACACTGAGC TTGTGGAGAC
B*40:55 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
cDNA 780 790 800 810 820 830 840 850 860 870
B*40:01:01 CAGACCAGCA GGAGATAGAA CCTTCCAGAA GTGGGCAGCT GTGGTGGTGC CTTCTGGAGA AGAGCAGAGA TACACATGCC ATGTACAGCA TGAGGGGCTG
B*40:55 ---------- ---------- ---------- ---------- ---A------ ---------- ---------- ---------- ---------- ----------
cDNA 880 890
B*40:01:01 CCGAAGCCCC TCACCCTGAG ATGGG
B*40:55 ---------- ---------- -----
Fig. 3. Comparison of DNA sequences between HLA-40:55 and -B*40:01:01 in exons 2, 3 and 4. The DNA sequence of B*40:55 is identical to B*40:01:01 in exons 2, 3 and 4 except at
residue 814 where the G of B*40:01:01 is replaced by A (shaded). cDNA ¼ complementary DNA.
AA Pos.  10 20 30  40  50 60 70 80  90 100
B*40:01:01 GSHSMRYFHT AMSRPGRGEP RFITVGYVDD TLFVRFDSDA TSPRKEPRAP WIEQEGPEYW DRETQISKTN TQTYRESLRN LRGYYNQSEA GSHTLQRMYG
B*40:55 *--------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
AA Pos. 110 120  130 140 150 160   170  180  190 200
B*40:01:01 CDVGPDGRLL RGHNQYAYDG KDYIALNEDL RSWTAADTAA QISQRKLEAA RVAEQLRAYL EGECVEWLRR YLENGKDKLE RADPPKTHVT HHPISDHEAT
B*40:55 ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
AA Pos. 210 220  230  240 250 260   270
B*40:01:01 LRCWALGFYP AEITLTWQRD GEDQTQDTEL VETRPAGDRT FQKWAAVVVP SGEEQRYTCH VQHEGLPKPL TLRW
B*40:55 ---------- ---------- ---------- ---------- -------M-- ---------- ---------- ----
Fig. 4. Comparison of amino acid sequences between HLA-40:55 and -B*40:01:01 in exons 2, 3 and 4. The amino acid sequence of B*40:55 is identical to B*40:01:01 in exons 2, 3
and 4 except at residue 248 where the V of B*40:01:01 is replaced by M (shaded). HLA ¼ human leukocyte antigen.
K.-L. Yang, P.-Y. Lin / Tzu Chi Medical Journal 26 (2014) 21e24 23B*40:55 may be deduced: A*02:07-B*40:55-DRB1*04:05 and
A*26:01-B*40:55-DRB1*09:01. We postulate that the B*40:55-
associated haplotype A*02:07-B*40:55-DRB1*04:05 is most prob-
ably conserved in Taiwanese people because of its presence in
Taiwanese population, whereas the other B*40:55-associated HLA
haplotype, A*26:01-B*40:55-DRB1*09:01, is probably conserved in
Taiwanese and Japanese population. These speculations await
future veriﬁcation.
4. Discussion
In this study we conﬁrmed the DNA sequence of two low-
frequency HLA alleles, A*31:30 and B*40:55. We validated the
Taiwanese ethnicity of A*31:30 and the Asian ethnicity of B*40:55.
We further deduced the probable HLA haplotypes in association
with A*31:30 and B*40:55 based on the common alleles shared by
the blood donors carrying A*31:30 and B*40:55. We further
postulated the two HLA haplotypes in association with B*40:55 in
the Asian populations. Information about the ethnicity of carriers of
A*31:30 and B*40:55 and their linked HLA haplotypes can be used
in anthropological investigations of race in addition to allowing
search coordinators from unrelated bone marrow donor registries
to allocate appropriate unrelated bonemarrow hematopoietic stem
cell donors for their patients.It is worth mentioning that the classical and most direct method
of determining HLA haplotype is through family study if test ma-
terials from a number of key family members are available. Alter-
natively, population study may be used if a sufﬁcient number of
unrelated donors are available [7]. However, the haplotypes
deduced through population investigation are only considered
likely or most probable. In this study, because of the availability of
the necessary test materials, we opted to determine the haplotypes
by looking at the HLA alleles carried in common by unrelated do-
nors with the same alleles of interest. By the same token, if deter-
mination of plausible HLA haplotypes is for rare HLA alleles, alleles
shared in common by unrelated individuals may be used to deduce
the probable associated haplotypes [7e16]. The frequencies of
A*31:30 and B*40:55 in the Taiwanese population are extremely
low at about 1 in 20,000 to 1 in 30,000 according to our HLA typing
practice. Therefore, we think the probable HLA-A*31:30 and HLA-
B*40:55-associated haplotypes that we postulated in this study are
highly reliable.
The HLA alleles are increasing exponentially with the recent
development of DNA-based molecular typing technology. By
contrast, HLA diversity in every ethnic group is unique and
important. Finding appropriate HLA-matched unrelated bone
marrow stem cell donors for a given needy patient for successful
stem cell transplantations relies on the accuracy of HLA typing
K.-L. Yang, P.-Y. Lin / Tzu Chi Medical Journal 26 (2014) 21e2424results and the spirit and strength to resolve unknown, discrepant,
and ambiguous genes in the HLA system.
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